ENTRY       D10333                      Drug
NAME        Elosulfase alfa (USAN);
            Elosulfase alfa (genetical recombination) (JAN);
            Vimizim (TN)
PRODUCT     VIMIZIM (BioMarin Pharmaceutical)
FORMULA     C5020H7588N1364O1418S34
EXACT_MASS  110755.4086
MOL_WEIGHT  110824.4607
SEQUENCE    APQPPNILLL LMDDMGWGDL GVYGEPSRET PLCSPSRAAL LTGRLPIRNG FYTTNAHARN
            LLKKAGYVSK IVGKWHLGHR PQFHPLKHGF NIPVYRDWEM VGRYYEEFPI NLKTGEANLT
            FLYWAVDATH APVYASKPFL GTSQRGRYGD VADNTFVFFT SDNGAALISA PEQGGSNGPF
            PGHVTAGQVS HQLGSIMDLF TTSLALAGLT LMDRPIFYYR GDTLMAATLG QHKAHFWTWT
            VTTHNLEDHT KLPLIFHLGR DPGERFPLSF EALVPAQPQL NVCNWAVMNW APPGCEKLGK
            PNLDRMAAEG LLFPNFYSAN AYTPQEIVGG IPDSEQLLPE DEWFGSPNCH FGPYDNKARP
            QIYLQEALDF IKRQARHHPF AVREIDDSIG KILELLQDLH LCGKQTTFEG GMREPALAWW
            PPSDRAIDGL NLLPTLLQGR NSWENFRQGI DFCPGQNVSG ASAEYQEALS RITSVVQQHQ
            CLTPPESIPK KCLWSH
            (Disulfide bridge: 139-139' 282-393 282'-393' 463-492 463'-492' 475-481 475'-481')
  TYPE      Peptide
REMARK      Therapeutic category: 3959
            ATC code: A16AB12
            Product: D10333<JP/US>
EFFICACY    Lysosomal storage disease treatment, Enzyme replacement (N-acetylgalactosamine-6-sulfatase)
  DISEASE   Mucopolysaccharidosis type IVA [DS:H00123]
  TYPE      Enzyme replacement therapy product
TARGET      GALNS* [HSA_VAR:2588v1] [HSA:2588] [KO:K01132]
  PATHWAY   hsa00531(2588)  Glycosaminoglycan degradation
            hsa04142(2588)  Lysosome
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
               A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
                A16AB Enzymes
                 A16AB12 Elosulfase alfa
                  D10333  Elosulfase alfa (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Elosulfase Alfa
               D10333  Elosulfase alfa (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               395  Enzyme preparations
                3959  Others
                 D10333  Elosulfase alfa (USAN); Elosulfase alfa (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Sulfatases
                GALNS* [HSA_VAR:2588v1]
                 D10333  Elosulfase alfa (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10333
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10333
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10333
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10333
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D10333
DBLINKS     CAS: 9025-60-9
            PubChem: 172232427
///
